###begin article-title 0
###xml 80 88 <span type="species:ncbi:9606">Patients</span>
Clinical Significance of Epigenetic Inactivation of hMLH1 and BRCA1 in Tunisian Patients with Invasive Breast Carcinoma
###end article-title 0
###begin p 1
Recommended by Xin-yuan Guan
###end p 1
###begin p 2
###xml 302 316 302 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">mutL homolog 1</italic>
###xml 318 330 318 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">colon cancer</italic>
###xml 332 351 332 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nonpolyposis type 2</italic>
###xml 353 360 353 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 373 388 373 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">breast cancer 1</italic>
###xml 390 401 390 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">early onset</italic>
###xml 577 578 577 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 622 623 622 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 692 693 692 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 741 742 741 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 846 847 846 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 883 884 883 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 128 133 <span type="species:ncbi:9606">human</span>
###xml 353 360 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 446 454 <span type="species:ncbi:9606">patients</span>
Aberrant hypermethylation of gene promoter regions is one of the mechanisms for inactivation of tumour suppressor genes in many human cancers including breast carcinoma. In the current study, we aimed to assess by MSP, the methylation pattern of two cancer-related genes involved in DNA repair: hMLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) and BRCA1 (breast cancer 1, early onset) in 78 primary breast cancers from Tunisian patients. The methylation frequencies were 24.36% for hMLH1 and 46% for BRCA1. BRCA1 methylation correlated with age at diagnosis (P = .015) and 5-years disease free survival (P = .016) while hMLH1 methylation was more frequent in larger tumors (P = .002) and in presence of distant metastasis (P = .004). Furthermore, methylation of hMLH1 significantly correlated with high level of P53 expression (P = .006) and with overall survival (P = .015) suggesting that silencing of hMLH1 through aberrant promoter methylation could be used as a poor prognosis indicator in breast cancer.
###end p 2
###begin title 3
1. Introduction
###end title 3
###begin p 4
###xml 164 165 164 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 296 297 296 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 484 485 484 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 561 562 561 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 690 691 690 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 59 64 <span type="species:ncbi:9606">women</span>
###xml 474 482 <span type="species:ncbi:9606">patients</span>
Breast cancer is the first cause of cancer mortality among women worldwide and the overall lifetime risk for developing invasive breast cancer is estimated to 10% [1]. In Tunisia, breast cancer is the second most frequent cancer among females and in the south area the incidence is of 30/100000 [2]. Tunisian breast cancer is characterized by a particular aggressive profile compared with Western countries as the incidence is more prevalent in young (<35 years) than older patients [3]. Breast cancer results of abnormal genetic as well as epigenetic changes [4]. Promoter-CpG islands hypermethylation, associated with global hypomethylation, are common molecular defects in cancer cells [5].
###end p 4
###begin p 5
###xml 238 239 238 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 570 571 570 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 572 573 572 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
CpG islands, frequently located at the 5'-end regulatory regions of genes, are subject to epigenetic modifications including DNA methylation and histone modification that are known to play an important role in regulating gene expression [5]. In normal cells, the majority of promoter CpG islands are protected from this epigenetic event and thus they are unmethylated. Conversely, in cancer cells, several promoter CpG islands are hypermethylated and form a closed repressive chromatin configuration that affects the transcription initiation of the corresponding genes [6-8]. 
###end p 5
###begin p 6
###xml 203 204 203 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
In breast cancer, more than 40 genes have been shown to be inactivated by methylation including those involved in DNA repair, cell-cycle regulation, tumor suppression, cell adhesion and cell signalling [9-12]. The identification of these methylated genes has significantly contributed to elucidate the molecular pathways which are altered in breast carcinoma and provided potential targets for molecular detection. 
###end p 6
###begin p 7
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 164 172 <span type="species:ncbi:9606">patients</span>
###xml 330 334 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 375 383 <span type="species:ncbi:9606">patients</span>
Recent studies suggested that methylation profiles of cancers depend on tumor type and ethnicity [13, 14]. In this context, the methylation status of breast cancer patients from Western population is well documented whereas that of Tunisian breast cancer is still not well studied except a recent work on the relationship between SV40 status and promoter hypermethylation in patients from the central region of Tunisia [15]. 
###end p 7
###begin p 8
###xml 125 185 125 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)</italic>
###xml 197 225 197 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">breast cancer 1, early onset</italic>
###xml 177 184 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 344 352 <span type="species:ncbi:9606">patients</span>
Therefore, our study was initiated with the aim to assess the methylation profile of two genes involved in DNA repair: hMLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) and BRCA1 (breast cancer 1, early onset). We next explored for associations between gene methylation and clinicopathological features, hormone receptors, and patients survival. 
###end p 8
###begin p 9
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 679 681 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
BRCA1 and hMLH1 have been shown to be methylated in tumors leading to the downregulation of gene expression [16-20]. The hMLH1 gene is a member of the DNA mismatch repair system which corrects DNA base-pairing errors in newly replicated DNA [21]. Deficiencies in this system result in mutation rates 100-fold higher than those observed in normal cells [22, 23]. Besides its involvement in DNA repair, BRCA1 is a tumor suppressor gene located on 17q12-21. Loss of the wild-type allele (LOH) is required for tumorigenesis in germ line mutation carriers. Hypermethylation of the BRCA1 promoter has been shown to be one of the mechanisms leading to functional inactivation of BRCA1 [24]. 
###end p 9
###begin title 10
2. Material and Methods
###end title 10
###begin title 11
###xml 5 13 <span type="species:ncbi:9606">Patients</span>
2.1. Patients Characteristics
###end title 11
###begin p 12
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 466 475 466 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Clinical-</italic>
###xml 592 599 592 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
A total of 78 fresh-frozen primary breast cancer tissues were collected from the Anatomo-Pathology; CHU Habib Bourguiba of Sfax in Tunisia with Institutional Review Board approval. The age at diagnosis ranged from 28 to 73 years, with a mean of 50.6. All cases were graded according to the modified Scarff- Bloom-Richardson system [25]. The clinical stage of the disease was determined according to TNM classification of the International Union Against Cancer [26]. Clinical-pathological data (age, histological grade, tumor size, lymph node status, and distant metastasis) are summarized in Table 1. 
###end p 12
###begin title 13
2.2. DNA Extraction
###end title 13
###begin p 14
###xml 214 216 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 266 268 260 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 323 325 316 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
Genomic DNA was extracted from fresh-frozen specimens using the standard protocol with Proteinase K in the presence of SDS at 37degreesC overnight, followed by phenol/chloroform extraction as described previously [27]. Briefly tissues sections were incubated in 100 muL TE (10 mM Tris-Hcl, pH 8.0, 1 mM EDTA) containing 40 mug proteinase K at 55degreesC for 4 hours. DNA was extracted with a mixture of phenol-chloroform-isoamyl alcohol (25 : 24 : 1) and precipitated with ethanol at -20degreesC. The quantity of DNA was checked by spectrophotometer and stored at -20degreesC for further use.
###end p 14
###begin title 15
2.3. Methylation-Specific-PCR (MSP)
###end title 15
###begin p 16
###xml 20 22 20 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 346 348 345 347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 431 438 430 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
DNA samples (1 to 2 mug) were modified with sodium bisulfite that converts the unmethylated cytosines but not the methylated ones to uracil using the Methyl Detector Kit as recommended by Active Motif (Belgium). The bisulfite-treated DNA was amplified using specific primers for methylated and unmethylated alleles as described by Herman et al. [28]. Sequences of the primers, annealing temperature, and product size are listed in Table 1.
###end p 16
###begin p 17
###xml 44 46 44 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 61 63 60 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 90 92 88 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#956;</italic>
###xml 111 112 108 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 349 356 328 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
PCR was carried out in a total volume of 25 muL containing 2 muM of each primer pair, 200 muM dNTP, 1.5 mM MgCl2, 1X PCR buffer, and 1 U of Taq DNA polymerase (Fermentas). Each PCR reaction underwent initial denaturation at 95degreesC for 10 minutes, and 35 cycles of the following profile: 30 seconds at 94degreesC, 30 seconds at optimal Tdegrees (Table 1), and 30 seconds at 72degreesC followed by a final 10 minutes extension at 72degreesC. Fully methylated DNA (Active Motif, Belgium) and lymphocytes DNA from healthy individual were used as positive controls for the methylated and unmethylated reactions, respectively. Blank control without DNA was included in each PCR assay. After amplification, products were electrophoresed using 2% agarose gels, stained with ethidium bromide and visualized under UV illumination.
###end p 17
###begin title 18
2.4. Immunohistochemistry
###end title 18
###begin p 19
Immunostaining of Estrogen (ER) and Progesteron (PR) receptors was performed for all specimens, while HER/neu and p53 protein expression was investigated in 64 and 39 specimens, respectively. Four micrometers sections attached on silanized slides were de-waxed in xylene, rehydrated in graded ethanol, and covered with 10 mM citrate buffer (pH 6). Slides were incubated for 30 minutes with primary monoclonal antibodies against: ER (Dako, clone 1D5, 1 : 25), PR (Dako, clone PgR636, 1 : 50), HER2/neu (Dako, clone 124, 1 : 100), and p53 (clone DO-7, Dako Cytomation 1 : 50) followed by incubation with biotin-labelled secondary antibodies. The streptavidin-peroxidase complex was visualized using diaminobenzidine as a chromogenic substrate. All slides were evaluated without knowledge of the clinical outcome. Sections were considered to be positive if more than 5% of tumor cells were stained. For each run of staining, positive control slides were prepared from breast carcinoma known to be positive for the proteins under study. The HER2/neu and p53 immunostaining were scored from 0 to 3 according to the criteria set by Dako. The staining was scored as negative (0) when no membrane staining was observed for HER2/neu, and no nuclear staining for p53, or when staining was observed in less than 10% of the tumor cells, weak positive (1+) if weak focal staining was seen in more than 10% of the tumor cells, intermediate (2+), if weak to moderate, complete staining was seen in more than 10% of the tumor cells and strongly positive (3+) if intense and complete staining in more than 10% of the tumor cells. In the final analysis, scores 0, 1, and 2 were considered as negative, only score 3 was retained as positive in HER2/neu overexpression cases. However, scores 0 and 1 were negative and score 2 and 3 were considered as positive for p53.
###end p 19
###begin title 20
2.5. Data Analysis and Statistics
###end title 20
###begin p 21
###xml 104 107 104 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#967;</italic>
###xml 445 446 443 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 586 587 584 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The association between aberrant hypermethylation and clinicopathological parameters was checked by the chi2 test. All variables (age, stage, histological grade, lymph node involvement, distal metastasis, hormone receptor status, and CpG island hypermethylation) were also subjected to multivariate analysis using Logistic regression. Survival curves were constructed according to the method of Kaplan Meier. For differences between curves, the P value was calculated using the log rank test. All the statistical analysis was performed using the software SPSS for Windows version 13.0. P < .05 was considered as statistically significant.
###end p 21
###begin title 22
3. Results and Discussion
###end title 22
###begin title 23
3.1. Methylation Profiles of BRCA1 and hMLH1 in Tumor Tissues
###end title 23
###begin p 24
###xml 379 380 379 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 381 382 381 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 513 522 513 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1 </xref>
Aberrant methylation of the promoter region is considered as one of the major mechanisms for silencing of cancer-related genes, resulting in downregulation of gene expression. It has been demonstrated that CpG islands hypermethylation is implicated in the loss of expression of critical tumor suppressor and growth regulatory genes leading to cancer development and progression [5-8]. Analysis of promoter methylation of BRCA1 and hMLH1 was carried out in 78 and 74 invasive primary breast tissues, respectively. Figure 1 shows representative examples of MSP results. The frequency of promoter hypermethylation was 44.8% (35 out of 78) for BRCA1 and 24.3% (17 out of 74) for hMLH1. Among the 78 malignant tissues, more than a half exhibited at least one methylated gene (62%). In other hand, for some samples, we observed both the methylated and unmethylated alleles, this can be probably explained by the presence of infiltrating lymphocytes and/or nonmalignant epithelial cells in the primary tumors.
###end p 24
###begin p 25
###xml 123 125 123 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 169 249 169 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1 and hMLH1 methylation were in the middle of the range of previous studies.</italic>
 When we reviewed the literature, the methylation frequency ranged from 8 to 43.5% for hMLH1 and from 11 to 60% for BRCA1 [20, 29-32]. In our series, the frequencies of BRCA1 and hMLH1 methylation were in the middle of the range of previous studies. These differences may be explained by several factors: (i) unmethylated DNA from the normal cells infiltrating the tumor might attenuate the methylation levels and (ii) number of CpG within the region of interest. To avoid misinterpretation of our results, we included in each assay, both methylated and unmethylated DNA as controls. 
###end p 25
###begin p 26
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 506 508 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 216 224 <span type="species:ncbi:9606">patients</span>
###xml 416 421 <span type="species:ncbi:9606">women</span>
On the other hand, several investigations have attempted to identify the racial/ethnic differences in promoter hypermethylation. Bae et al. evaluated promoter methylation status in American and Korean breast cancers patients and they found no significant interethnic differences [13]. More recently, it was reported that there are many similarities of promoter hypermethylation profiles between Korean and Caucasian women, but also dissimilarities that characterize tumors of one ethnicity from the other [14].
###end p 26
###begin title 27
3.2. Relationship between Methylation Status and Clinicopathological Characteristics
###end title 27
###begin p 28
###xml 129 136 129 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2</xref>
###xml 232 233 232 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 242 249 242 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2</xref>
###xml 799 800 797 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 831 838 829 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab3">Table 3</xref>
###xml 264 272 <span type="species:ncbi:9606">patients</span>
###xml 447 452 <span type="species:ncbi:9606">women</span>
###xml 585 593 <span type="species:ncbi:9606">patients</span>
The relationship between promoter hypermethylation of hMLH1 and BRCA1 genes and clinicopathological parameters was summarized in Table 2. Statistical analysis showed that BRCA1 hypermethylation was associated with age at diagnosis (P = .015, Table 2) since 72% of patients </=45 years displayed the methylated pattern. This observation suggests that loss of BRCA1 expression through aberrant promoter methylation occurred more frequently in young women with breast carcinoma which is known to have a particular more aggressive feature. Despite age, no other association was found with patients' characteristics and BRCA1 methylation status. Nevertheless, by multivariate analysis, we found a significant association of BRCA1 promoter methylation with clinical stage, tumor size and 5-year survival (P = .022, .037 and .017, resp., Table 3). 
###end p 28
###begin p 29
###xml 122 123 122 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 148 155 148 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2</xref>
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 490 492 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 800 801 800 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 929 930 929 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 939 946 939 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2</xref>
The most consistent associations were seen between hMLH1 promoter hypermethylation and tumor size and distant metastasis (P = .002 and .004, resp., Table 2). This result leads us to suggest that hypermethylation of hMLH1 gene promoter seemed to confer advantage for tumors cells invasion, and it may be used as a marker of advanced breast cancer. In this context, it was reported that hypermethylation of hMLH1 was significantly associated with advanced stage and lymphatic metastasis [19, 29]. Our finding is consistent with those studies since a trend of association was found between methylated hMLH1 profile and clinical stage of breast cancer. In fact, 14.3% of hMLH1 methylated tumors are of stage T III, IV versus 4.8% of early stage although the difference was not statistically significant (P = .276). Furthermore, we detected a significant correlation between response to treatment and hMLH1 methylation by univariate (P = .004, Table 2).
###end p 29
###begin title 30
3.3. Relationship between Methylation of Individual Genes and ER, PR, HER2/neu, and P53 Status
###end title 30
###begin p 31
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 455 456 455 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 458 465 458 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
###xml 559 560 559 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 569 576 569 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab1">Table 1</xref>
###xml 1025 1027 1025 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 1176 1178 1176 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 1362 1364 1362 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
The ER, PR, and HER2/neu are important prognostic biomarkers and therapeutic targets in primary breast cancer. ER-negative tumors appear to be more malignant, resulting in a poorer prognosis than ER-positive tumors [33, 34]. Expression of HER2/neu, ER, and PR proteins are considered as predictive marker for response to hormone therapy in breast cancer. High to moderate level of ER expression was detected in 60.3% of tumors while 39.7% of cases were ER- (Table 1). Univariate analysis, revealed that ER status was weakly associated with hMLH1 methylation (P = .054, Table 1). No other significant association between the methylation profile of hMLH1 or BRCA1 and PR, HER2/neu status was noted in our series. In breast cancer, methylation has already been connected to hormone regulation, but the correlation is not clear yet. Campan et al., reviewed the DNA methylation profiles of breast, endometrial, ovarian, and proximal colon cancers but did not find evidence for global hormone-specific DNA methylation alterations [35]. On the other hand, Widschwendter et al. reported significant differences in hormone receptor status between clusters of DNA methylation profiles [36]. Recently, it was demonstrated that epigenetic differences between ER-positive and ER-negative breast tumors arise early in cancer development and persist during cancer progression [37].
###end p 31
###begin p 32
###xml 132 141 132 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2 </xref>
###xml 328 329 328 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 338 345 338 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab2">Table 2</xref>
###xml 347 355 347 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 415 425 415 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">methylated</italic>
###xml 612 613 612 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 616 617 616 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 619 620 619 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 634 635 634 635 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 640 641 640 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 643 644 643 644 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 653 660 653 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab4">Table 4</xref>
###xml 685 686 685 686 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 689 690 689 690 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 695 696 695 696 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 698 699 698 699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 707 714 707 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tab4">Table 4</xref>
###xml 868 870 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 987 989 987 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 1092 1093 1092 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1434 1436 1434 1436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 1550 1552 1550 1552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
In the current study, p53 expression was assessed by IHC in 39 specimens. Nuclear staining was seen in 41% (16 out of 39) of cases. Figure 2 shows an example of specimen with p53 positive (a) and negative (b) nuclear staining. Interestingly, we found that all tumors displaying unmethylated hMLH1 profile were negative for p53 (P = .006, Table 2, Figure 2). This observation suggests a positive association between methylated hMLH1 and functional p53. Furthermore, p53 expression was significantly connected to hormone receptor status. Indeed, high level of p53 expression was associated with double negative (ER-/PR-, P = .001 and ER-/HER2-, P = .011, Table 4) and triple negative (ER-/PR-/HER2-, P = .01, Table 4) tumors. Our data was consistent with previously reported results showing that triple negative breast cancers correlated with high p53 expression level [37]. It was well established that triple negative breast cancer has aggressive clinical features and reduced survival [38]. In the current work, we showed that triple negative breast cancer correlated with 5-year survival, (P = .002; OR = 0.083, 95%CI = 0.015-0.462) while no statistically significant association was found with overall survival and triple negative tumors in our series. Recently, Rhee et al., reported that most of the relapses in triple negative breast cancer occur within the first 3 years, in contrast to tumors expressing ER, PR, and HER2/neu [37]. Altogether, these findings reflect the aggressiveness of triple negative breast cancer as previously reported [38].
###end p 32
###begin title 33
3.4. Relationship between Methylation of hMLH1 and Overall Survival
###end title 33
###begin p 34
###xml 216 224 216 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3</xref>
###xml 359 360 359 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 738 739 738 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 895 897 895 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 226 234 <span type="species:ncbi:9606">patients</span>
###xml 487 495 <span type="species:ncbi:9606">patients</span>
###xml 809 817 <span type="species:ncbi:9606">patients</span>
The survival rate was available for 34 patients and the follow-up time ranged from 3 to 119 months. The Kaplan-Meier method was used to correlate hMLH1 and BRCA1 methylation status with overall survival. As shown on Figure 3, patients with unmethylated hMLH1 gene promoter have a significant prolonged survival rate compared to those with methylated profile (P log rank = .015). To the best of our knowledge, this is the first report about the involvement of hMLH1 hypermethylation with patients' outcome suggesting that it could be an important prognostic factor of breast cancer. However this finding should be confirmed on larger series. In the current study, BRCA1 methylation and survival association was of borderline significance (P log-rank = .065). Recently, it was reported in a large cohort of 851 patients that BRCA1 methylation was associated with breast cancer-specific mortality [39].
###end p 34
###begin title 35
4. Conclusion
###end title 35
###begin p 36
###xml 328 336 <span type="species:ncbi:9606">patients</span>
In summary, we examined BRCA1 and hMLH1 promoter methylation status and explored the relationship with clinicopathological factors and breast cancer survival. Promoter methylation of hMLH1 was more frequent in cancers with distant metastasis and in larger tumors (greater than 3 cm) whereas BRCA1 hypermethylation was higher in patients under 45 years. Furthermore, aberrant methylation of hMLH1 correlated with reduced overall survival while BRCA1 hypermethylation associated with 5-year survival. Our results indicate that BRCA1 and hMLH1 promoter methylation could be an important prognostic factor of breast cancer.
###end p 36
###begin title 37
Acknowledgments
###end title 37
###begin p 38
This work was supported by a Grant of the "Ministere de l'Enseignement Superieur et de la Recherche Scientifique Tunisien". The authors would like to thank all clinicians and pathologists at CHU Habib Bourguiba at Sfax-Tunisia, and Dr. Khemais Ben-Hadj for critical suggestions.
###end p 38
###begin article-title 39
The lifetime risk of developing breast cancer
###end article-title 39
###begin article-title 40
Epidemiologic features of rapidly progressing breast cancer in Tunisia
###end article-title 40
###begin article-title 41
Breast Cancer
###end article-title 41
###begin article-title 42
###xml 34 39 <span type="species:ncbi:9606">human</span>
Biological and molecular basis of human breast cancer
###end article-title 42
###begin article-title 43
The fundamental role of epigenetic events in cancer
###end article-title 43
###begin article-title 44
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future
###end article-title 44
###begin article-title 45
###xml 35 40 <span type="species:ncbi:9606">human</span>
A gene hypermethylation profile of human cancer
###end article-title 45
###begin article-title 46
Epigenetic gene silencing in cancer: a mechanism for early oncogenic pathway addiction?
###end article-title 46
###begin article-title 47
Epigenetics and breast cancer
###end article-title 47
###begin article-title 48
Quantitative assessment of promoter hypermethylation during breast cancer development
###end article-title 48
###begin article-title 49
DNA methylation and breast carcinogenesis
###end article-title 49
###begin article-title 50
DNA methylation and breast cancer
###end article-title 50
###begin article-title 51
Hypermethylation in histologically distinct classes of breast cancer
###end article-title 51
###begin article-title 52
###xml 190 195 <span type="species:ncbi:9606">women</span>
A comparative study of Korean with Caucasian breast cancer reveals frequency of methylation in multiple genes correlates with breast cancer in young, ER, PR-negative breast cancer in Korean women
###end article-title 52
###begin article-title 53
###xml 46 51 <span type="species:ncbi:9606">human</span>
Evidence for a role of the Simian Virus 40 in human breast carcinomas
###end article-title 53
###begin article-title 54
Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics
###end article-title 54
###begin article-title 55
Tumor specific distribution of BRCA1 promoter region methylation supports a pathogenic role in breast and ovarian cancer
###end article-title 55
###begin article-title 56
Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours
###end article-title 56
###begin article-title 57
Genetic and epigenetic modification of mismatch repair genes hMSH2 and hMLH1 in sporadic breast cancer with microsatellite instability
###end article-title 57
###begin article-title 58
Roles of mismatch repair proteins hMSH2 and hMLH1 in the development of sporadic breast cancer
###end article-title 58
###begin article-title 59
###xml 48 53 <span type="species:ncbi:9606">human</span>
Structure and function of the components of the human DNA mismatch repair system
###end article-title 59
###begin article-title 60
Microsatellite instability and mismatch repair defects in cancer
###end article-title 60
###begin article-title 61
The multifaceted mismatch-repair system
###end article-title 61
###begin article-title 62
BRCA1 methylation: a significant role in tumour development?
###end article-title 62
###begin article-title 63
Role of pathology in the prognosis and management of breast cancer
###end article-title 63
###begin article-title 64
Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands
###end article-title 64
###begin article-title 65
###xml 114 119 <span type="species:ncbi:9606">women</span>
Hypermethylation analysis of mismatch repair genes (hmlh1 and hmsh2) in locally advanced breast cancers in Indian women
###end article-title 65
###begin article-title 66
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer
###end article-title 66
###begin article-title 67
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy
###end article-title 67
###begin article-title 68
DNA hypermethylation in breast cancer and its association with clinicopathological features
###end article-title 68
###begin article-title 69
Estrogen receptors: role in breast cancer
###end article-title 69
###begin article-title 70
Breast cancer risk factors according to joint estrogen receptor and progesterone receptor status
###end article-title 70
###begin article-title 71
###xml 58 63 <span type="species:ncbi:9606">human</span>
DNA methylation profiles of female steroid hormone-driven human malignancies
###end article-title 71
###begin article-title 72
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen
###end article-title 72
###begin article-title 73
The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer
###end article-title 73
###begin article-title 74
What is triple-negative breast cancer?
###end article-title 74
###begin article-title 75
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRCA1</italic>
###xml 72 77 <span type="species:ncbi:9606">women</span>
BRCA1 promoter methylation is associated with increased mortality among women with breast cancer
###end article-title 75
###begin p 76
###xml 430 431 430 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Electrophoresis of PCR products spanning the BRCA1 and hMLH1 promoters from bisulfite-treated DNA in breast cancer tissues. Each lane contains products generated from separate PCR reactions using primers specific for unmethylated (U) or methylated (M) DNA template. Fully methylated DNA from Active Motif and Blood from healthy individual used as a positive control (C) for methylated and unmethylated DNA (B). The lanes marked (H2O) indicates water only without the addition of DNA and (L) 100-bp ladder as molecular weight markers (Fermentas).
###end p 76
###begin p 77
Representative result of p53 immunohistochemical staining and hMLH1 promoter methylation. (a) Breast tumor specimen with p53 nuclear positivity associated with both hMLH1 methylated and unmethylated DNA. (b) Breast tumor specimen negative for p53 correlated with unmethylated hMLH1 profile.
###end p 77
###begin p 78
Kaplan-Meier survival curve correlating overall survival with hMLH1 methylated and unmethylated profile.
###end p 78
###begin p 79
Summary of primer sequences, annealing temperature, product size and number of cycle used in MSP assay. M: methylated DNA, U: unmethylated DNA, F: forward, R: Reverse.
###end p 79
###begin p 80
Association between gene promoter methylation and clinicopathological features ER and p53 expression in breast cancer.
###end p 80
###begin p 81
DFS: Disease Free Survival, ER: Estrogen Receptor. 
###end p 81
###begin p 82
###xml 0 3 0 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(a)</sup>
(a)Data for DFS, response to radiotherapy, metastasis, and p53 status were not available for all specimens. 
###end p 82
###begin p 83
###xml 0 3 0 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(b)</sup>
(b)Comparisons of DFS and P53 status was made by Fisher's exact test and all other comparisons were by the 2 test.
###end p 83
###begin p 84
Multivariate analysis of BRCA1 methylation status and clinical features.
###end p 84
###begin p 85
###xml 64 65 64 65 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 68 69 68 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 73 74 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 79 81 79 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722; </sup>
###xml 106 107 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 110 111 110 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 116 117 116 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
Correlation between p53 expression level and double negative (ER-/PR-, ER-/HER2- ) and triple negative (ER-/PR-/HER2-) breast cancer.
###end p 85

